Alterations in circulating activin A, GDF-15, TGF-β3 and MMP-2, -3, and -9 during one year of left ventricular reverse remodelling in patients operated for severe aortic stenosis

European Journal of Heart Failure

Volumn 10, Issue 12, 2008, Pages 1201-1207

  Bjørnstad, Johannes L ^a,b,c   Neverdal, Nils O ^a,b   Vengen, Øystein A ^a,b   Knudsen, Cathrine Wold ^a   Husebye, Trygve ^a   Pepper, John ^d   Lie, Mons ^a,b   Christensen, Geir ^a,b,c   Tønnessen, Theis ^a,b,c  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Activin A; Aortic valve replacement; GDF 15; Growth factors; MMP; Myocardial remodelling; TGF

Indexed keywords

ACTIVIN A; GELATINASE A; GELATINASE B; GROWTH DIFFERENTIATION FACTOR 15; GROWTH FACTOR; STROMELYSIN; TRANSFORMING GROWTH FACTOR BETA3;

AGED; AORTA STENOSIS; AORTA VALVE REPLACEMENT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ECHOCARDIOGRAPHY; EXTRACELLULAR MATRIX; FEMALE; HEART VENTRICLE REMODELING; HEMODYNAMICS; HUMAN; MALE; MEASUREMENT; PHYSICAL PERFORMANCE; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; WALKING;

EID: 56349104521     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2008.09.010     Document Type: Article

References (29)

1. Huber D., Grimm J., Koch R., and Krayenbuehl H.P. Determinants of ejection performance in aortic stenosis. Circulation 64 (1981) 126-134
2. Opie L.H., Commerford P.J., Gersh B.J., and Pfeffer M.A. Controversies in ventricular remodelling. Lancet 367 (2006) 356-367
3. Lund O., Kristensen L.H., Baandrup U., et al. Myocardial structure as a determinant of pre- and postoperative ventricular function and long-term prognosis after valve replacement for aortic stenosis. Eur Heart J 19 (1998) 1099-1108
4. Perez de A.D., Lees B., Flather M., et al. Randomized comparison of stentless versus stented valves for aortic stenosis: effects on left ventricular mass. Circulation 112 (2005) 2696-2702
5. Krayenbuehl H.P., Hess O.M., Monrad E.S., Schneider J., Mall G., and Turina M. Left ventricular myocardial structure in aortic valve disease before, intermediate, and late after aortic valve replacement. Circulation 79 (1989) 744-755
6. Neverdal N.O., Knudsen C.W., Husebye T., et al. The effect of aortic valve replacement on plasma B-type natriuretic peptide in patients with severe aortic stenosis-one year follow-up. Eur J Heart Fail 8 (2006) 257-262
7. Tønnessen T., Giaid A., Saleh D., Naess P.A., Yanagisawa M., and Christensen G. Increased in vivo expression and production of endothelin-1 by porcine cardiomyocytes subjected to ischemia. Circ Res 76 (1995) 767-772
8. Woldbaek P.R., Tønnessen T., Henriksen U.L., et al. Increased cardiac IL-18 mRNA, pro-IL-18 and plasma IL-18 after myocardial infarction in the mouse; a potential role in cardiac dysfunction. Cardiovasc Res 59 (2003) 122-131
9. Euler-Taimor G., and Heger J. The complex pattern of SMAD signaling in the cardiovascular system. Cardiovasc Res 69 (2006) 15-25
10. Khan R., and Sheppard R. Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology 118 (2006) 10-24
11. Schiller M., Javelaud D., and Mauviel A. TGF-beta-induced SMAD signaling and gene regulation: consequences for extracellular matrix remodeling and wound healing. J Dermatol Sci 35 (2004) 83-92
12. Yndestad A., Ueland T., Øie E., et al. Elevated levels of activin A in heart failure: potential role in myocardial remodeling. Circulation 109 (2004) 1379-1385
13. Florholmen G., Halvorsen B., Beraki K., et al. Activin A inhibits organization of sarcomeric proteins in cardiomyocytes induced by leukemia inhibitory factor. J Mol Cell Cardiol 41 (2006) 689-697
14. Brown D.A., Breit S.N., Buring J., et al. Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study. Lancet 359 (2002) 2159-2163
15. Wollert K.C., Kempf T., Peter T., et al. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation 115 (2007) 962-971
16. Kempf T., Eden M., Strelau J., et al. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res 98 (2006) 351-360
17. Xu J., Kimball T.R., Lorenz J.N., et al. GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res 98 (2006) 342-350
18. Depre C., Shipley G.L., Chen W., et al. Unloaded heart in vivo replicates fetal gene expression of cardiac hypertrophy. Nat Med 4 (1998) 1269-1275
19. Spinale F.G. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 87 (2007) 1285-1342
20. Kelly D., Cockerill G., Ng L.L., et al. Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. Eur Heart J 28 (2007) 711-718
21. Hirota H., Yoshida K., Kishimoto T., and Taga T. Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci U S A 92 (1995) 4862-4866
22. Matsui H., Fujio Y., Kunisada K., Hirota H., and Yamauchi-Takihara K. Leukemia inhibitory factor induces a hypertrophic response mediated by gp130 in murine cardiac myocytes. Res Commun Mol Pathol Pharmacol 93 (1996) 149-162
23. Matsuse T., Ikegami A., Ohga E., et al. Expression of immunoreactive activin A protein in remodeling lesions associated with interstitial pulmonary fibrosis. Am J Pathol 148 (1996) 707-713
24. Ohga E., Matsuse T., Teramoto S., et al. Effects of activin A on proliferation and differentiation of human lung fibroblasts. Biochem Biophys Res Commun 228 (1996) 391-396
25. Patella S., Phillips D.J., Tchongue J., de Kretser D.M., and Sievert W. Follistatin attenuates early liver fibrosis: effects on hepatic stellate cell activation and hepatocyte apoptosis. Am J Physiol Gastrointest Liver Physiol 290 (2006) G137-G144
26. Wada W., Kuwano H., Hasegawa Y., and Kojima I. The dependence of transforming growth factor-beta-induced collagen production on autocrine factor activin A in hepatic stellate cells. Endocrinology 145 (2004) 2753-2759
27. Ohnishi N., Miyata T., Ohnishi H., et al. Activin A is an autocrine activator of rat pancreatic stellate cells: potential therapeutic role of follistatin for pancreatic fibrosis. Gut 52 (2003) 1487-1493
28. Kelly D., Khan S., Cockerill G., et al. Circulating stromelysin-1 (MMP-3): a novel predictor of LV dysfunction, remodelling and all-cause mortality after acute myocardial infarction. Eur J Heart Fail 10 (2008) 133-139
29. Tziakas D.N., Chalikias G.K., Papaioakeim M., et al. Comparison of levels of matrix metalloproteinase-2 and -3 in patients with ischemic cardiomyopathy versus nonischemic cardiomyopathy. Am J Cardiol 96 (2005) 1449-1451